Takeda Signs an Exclusive License Agreement with Poseida for Novel Non-Viral In Vivo Gene Therapies

Shots: The parties will initially develop up to 6 in vivo gene therapy programs utilizing Poseida’s piggyBac, Cas-CLOVER & biodegradable nanoparticle technology for 6 liver & HSC directed indications. Takeda has an option to add 2 additional programs and is obligated to provide funding for all program’s R&D costs Poseida to receive $45M up front …

Takeda Signs an Exclusive License Agreement with Poseida for Novel Non-Viral In Vivo Gene Therapies Read More »